Last reviewed · How we verify

NCT07050875

Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Acquired Brain Injury in a Clinical Setting

Completed NA Last updated 27 January 2026
What this trial tests

NA trial testing ABLE Exoskeleton in Acquired Brain Injury (Including Stroke) in 14 participants. Completed in 17 December 2025.

Timeline
30 June 2025
Primary endpoint
17 December 2025
17 December 2025

Quick facts

Lead sponsorABLE Human Motion S.L.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment14
Start date30 June 2025
Primary completion17 December 2025
Estimated completion17 December 2025
Sites3 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

ABLE Human Motion S.L.

Who can join

Adults 18 to 80, any sex, with Acquired Brain Injury (Including Stroke). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to validate the safety and clinical performance of the ABLE Exoskeleton device in people with acquired brain injury during a 10-session gait training program in a clinical setting. The secondary objective of the study focuses on obtaining preliminary data on the potential clinical and psychosocial benefits of the product.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ABLE Exoskeleton

Trials testing the same drug.

Other recruiting trials for Acquired Brain Injury (Including Stroke)

Currently open trials in the same condition.

Other ABLE Human Motion S.L. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07050875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing